$7.40
1.86% day before yesterday
Nasdaq, May 23, 10:01 pm CET
ISIN
US21833P1030
Symbol
CRBP
Sector
Industry

Corbus Pharmaceuticals Holdings Inc Stock price

$7.40
+0.01 0.14% 1M
-10.55 58.77% 6M
-4.40 37.29% YTD
-33.98 82.12% 1Y
-2.02 21.44% 3Y
-234.40 96.94% 5Y
-108.10 93.59% 10Y
Nasdaq, Closing price Fri, May 23 2025
-0.14 1.86%
ISIN
US21833P1030
Symbol
CRBP
Sector
Industry

Key metrics

Market capitalization $90.55m
Enterprise Value $-42.24m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.84
P/B ratio (TTM) P/B ratio 0.71
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-58.87m
Free Cash Flow (TTM) Free Cash Flow $-50.25m
Cash position $132.79m
EPS (TTM) EPS $-4.12
P/E forward negative
P/S forward 54.33
EV/Sales forward negative
Short interest 18.80%
Show more

Is Corbus Pharmaceuticals Holdings Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Corbus Pharmaceuticals Holdings Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Corbus Pharmaceuticals Holdings Inc forecast:

10x Buy
100%

Analyst Opinions

10 Analysts have issued a Corbus Pharmaceuticals Holdings Inc forecast:

Buy
100%

Financial data from Corbus Pharmaceuticals Holdings Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 17 17
21% 21%
-
- Research and Development Expense 42 42
79% 79%
-
-58 -58
59% 59%
-
- Depreciation and Amortization 0.52 0.52
15% 15%
-
EBIT (Operating Income) EBIT -59 -59
57% 57%
-
Net Profit -50 -50
49% 49%
-

In millions USD.

Don't miss a Thing! We will send you all news about Corbus Pharmaceuticals Holdings Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Corbus Pharmaceuticals Holdings Inc Stock News

Neutral
GlobeNewsWire
3 days ago
NORWOOD, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference, to be held June 3-5, 2025 in New York, NY.
Neutral
GlobeNewsWire
6 days ago
NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, effective May 15.
Neutral
GlobeNewsWire
about 2 months ago
NORWOOD, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology and obesity company with a diversified portfolio, announced today the dosing of the first subject in the single ascending dose / multiple ascending dose (SAD/MAD) portion of the Phase 1 trial of CRB-913 for the treatment of obesity. The study is being ...
More Corbus Pharmaceuticals Holdings Inc News

Company Profile

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded on December 18, 2013 and is headquartered in Norwood, MA.

Head office United States
CEO Yuval Cohen
Employees 28
Founded 2009
Website www.corbuspharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today